Evidence map›Paper›PMID 42106561›Full record

ArticleAnnals of biomedical engineering2026

Impact1: Supporting Innovation in Pediatric and Maternal Health-5 Years of Outcomes.

Elisabet Rosàs Canyelles, Juliana Perl, Marta Arenas-Jal, Antje Kirschner, Ignacio Andrés Pérez Romero, Mohit Singhala, Manikantam Gaddam, Anuradha Dayal, Yair J Blumenfeld, James K Wall and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Elisabet Rosàs CanyellesImpact1, Stanford Mussallem Center for Biodesign, 318 Campus Drive, Stanford, CA, 94305, USA. elirosas@stanford.edu.ORCID http://orcid.org/0000-0002-7640-5747
Juliana PerlImpact1, Stanford Mussallem Center for Biodesign, 318 Campus Drive, Stanford, CA, 94305, USA.
Marta Arenas-JalImpact1, Stanford Mussallem Center for Biodesign, 318 Campus Drive, Stanford, CA, 94305, USA.
Antje KirschnerImpact1, Stanford Mussallem Center for Biodesign, 318 Campus Drive, Stanford, CA, 94305, USA.
Ignacio Andrés Pérez RomeroImpact1, Stanford Mussallem Center for Biodesign, 318 Campus Drive, Stanford, CA, 94305, USA.
Mohit SinghalaImpact1, Stanford Mussallem Center for Biodesign, 318 Campus Drive, Stanford, CA, 94305, USA.
Manikantam GaddamImpact1, Stanford Mussallem Center for Biodesign, 318 Campus Drive, Stanford, CA, 94305, USA.
Anuradha DayalGeneral Pediatrics, Stanford University School of Medicine, 453 Quarry Road, Palo Alto, CA, 94304, USA.
Yair J BlumenfeldObstetrics & Gynecology - Maternal Fetal Medicine, Stanford Medicine Children's Health, 770 Welch Rd Ste 201, Palo Alto, CA, 94304, USA.
James K WallImpact1, Stanford Mussallem Center for Biodesign, 318 Campus Drive, Stanford, CA, 94305, USA.
Kunj ShethImpact1, Stanford Mussallem Center for Biodesign, 318 Campus Drive, Stanford, CA, 94305, USA.
Janene H FuerchImpact1, Stanford Mussallem Center for Biodesign, 318 Campus Drive, Stanford, CA, 94305, USA.

Funding

U.S. Food and Drug Administration P50FD006424
6 · The paper itself

Abstract

purposeImpact1 at the Stanford Mussallem Center for Biodesign was established in 2019 through its core partnership with UCSF as an FDA-funded Pediatric Device Consortium. We hypothesized that providing innovators in pediatric and maternal healthcare with mentorship, connections to experts, and grant funding would promote development, validation, approval, and commercialization of safe and effective health technologies for pediatric and maternal patients, and lead to positive broader impacts, measured as patients treated, capital raised, and jobs created.

methodsData were collected from 180 innovation teams supported by Impact1 between 2019 and 2024. Sources included intake forms, annual surveys, and public data. Key metrics analyzed included team demographics, innovation stage, resource utilization, funding raised, patients reached, and jobs created.

resultsImpact1 supported diverse teams across various stages of development with key resources including coaching, connections to experts, and funding opportunities. Since 2019, supported innovations have collectively treated an estimated 88,000 patients, raised $240 million, and created over 400 jobs.

conclusionsEvidence suggests that Impact1 resources positively influence the trajectory of early-stage medical device development in pediatric and maternal health. Future research will focus on establishing a more robust causal link between program resources and innovation outcomes.

Indexed as

InnovationMaternal healthMedical devicesPediatric health

Identifiers

PMID42106561

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.